戻る Agenda
Emerging Best Practices and Challenges in Strategic Drug Development and Design Decision Making
Session Chair(s)
Cara Willoughby, MS
Principal Scientific Advisor
IQVIA, United States
This session will present lessons learned and case examples from three different companies who have introduced change initiatives aimed at disrupting and improving strategy and design decision-making. Presentations will share common obstacles, change management pitfalls, critical success factors, and actions you can take now to improve design decision making in your company.
Learning Objective : Compare and contrast traditional versus emerging strategic drug development and design decision-making practices; Recognize challenges often encountered when implementing new tools, data, processes, and approaches to strategic drug development and design decision-making and describe their impact; Define critical success factors for improving strategic drug development and design decision-making
Speaker(s)
Lessons Learned Translating Data to Meaningful Design Insights
Cara Willoughby, MS
IQVIA, United States
Principal Scientific Advisor
Leveraging Big Data to Help Design Clinical Program Strategies
Kyle Holen, MD
Moderna, United States
Head of Development, Oncology and Therapeutics
Patient Engagement Strategies in Design
Florian Bieber, MD
Novartis Pharma AG, Switzerland
Global Head, Clinical Development and Analytics